About admin

This author has not yet filled in any details.
So far admin has created 89 blog entries.

RealWorld Dynamix™: Biologic and Otezla Switching in PsA 2017

Spherix Global Insights has released the 2017 update of RealWorld Dynamix: PsA based on analysis of 1,008 PsA patient charts. The large scale chart audit was completed by about 200 rheumatologists and focuses on patients that have been switched between biologic brands and/or Otezla during the past three months. In addition to comparisons from the

RealTime Dynamix™: Atopic Dermatitis Q2 2017

With two new entrants in the shape of Pfizer’s Eucrisa and Dupixent from Sanofi/Regeneron, the first ever biologic approved for atopic dermatitis (AD), the AD market is entering a period of real change. Just published RealTime Dynamix: Atopic Dermatitis Q2 2017 from Spherix Global Insights provides key insights on the shifting AD market. Click the

RealTime Dynamix™: Rheumatoid Arthritis EU Q1 2017

With the recent approval of two new JAK inhibitors and the imminent introduction of additional IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management. Spherix Global Insights recently released data collected from 257 rheumatologists in France, Germany, Italy, Spain and the UK, revealing a high unmet need for small molecules and alternate mechanism

Dupixent Delivers… and Sanofi-Regeneron Ushers in a New Era of Atopic Dermatitis (AD) Treatment

According to Spherix Global Insights, at just one month post-launch, nearly one-third of surveyed dermatologists (n=101) have prescribed Dupixent, although for some a burdensome reimbursement process is slowing the time from prescription to fulfillment. Download Report Overview EXTON, Pa., May 17, 2017 /PRNewswire/ -- According to the latest RealTime Dynamix™: Atopic Dermatitis report, just one

Novartis’ Cosentyx Takes the Wind Out of Stelara’s Sails in Psoriatic Arthritis Market

New findings in a recent study by Spherix Global Insights, RealWorld Dynamix™: Biologic and Otezla Switching in PsA, indicate an increased rate of switching to the brand and strong momentum for Cosentyx compared to previous results collected in November 2015 Download Report Overview EXTON, Pa., May 16, 2017 /PRNewswire/ -- A recent patient chart analysis